Unknown OBSERVATIONAL NCT05969379

Investigational Biomarkers for Neurological Immune-related Adverse Events (NFL-ICI)

Genetic Predisposition, Inflammation, and Neurodegeneration Biomarkers in Patients With Neurological Adverse Events of Immune Checkpoint Inhibitors: Correlation With Clinical Phenotypes and Outcome

Sponsor: Hospices Civils de Lyon

Conditions Neurological Disease

Interventions Analysis of biomarkers and their correlation with clinical characteristics and outcome

Updated 4 times since 2023 Last updated: Jul 28, 2023 Started: May 1, 2022 Primary completion: Dec 1, 2022 Completion: Dec 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Neurological Disease and is currently ongoing. Hospices Civils de Lyon leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Aug 2025 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Aug 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Sep 2023 — Jul 2024 [monthly]

Recruiting

First recorded

May 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospices Civils de Lyon

Data source: Hospices Civils de Lyon

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bron, France